· 13dVertex’s Journavx Changes the Pain Treatment Landscape But Opioids Here to Stay
Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a growing number of alternative approaches. Their ultimate uptake, however, remains to be seen.
Scientists believe this drug will be the first of a new wave of similar medications, ones that are both nonaddictive and ...
Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.
Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...
NIH-Funded Research Team Engineers New Drug Targeting Pain Sensation Pathway with Implications for Chronic Pain Treatment ...
Catarina Craveiro, a biomedical research technician from Lisbon, had been hobbled by lower back pain from scoliosis since ...
For the last quarter century, one of the world’s most capable drug developers toiled to make a new, non-addictive kind of painkiller. The journey was fittingly excruciating. Pain, as Vertex ...
SEVEN NEWS. HEY! WELCOME BACK. NEW PAIN MEDICATION HAS BEEN APPROVED BY THE FDA. IT SUPPOSEDLY NON-ADDICTIVE DARLENE MELENDEZ SPOKE WITH. UNM HEALTH EXPERT DOCTOR ASH ON HOW THIS WORKS.
Doctors typically prescribe drugs like gabapentin (used for epilepsy) or duloxetine (an antidepressant) to manage nerve pain.
U.S. researchers said Wednesday they have reproduced the pain-relieving effects of cannabis with a synthesized compound that ...
Tris Pharma’s opioid alternative has scored a third win in a trio of clinical trials, providing the biotech with the data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback